Clinical Trial Update: Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of Zevalin (yttrium-ibritumomab tiuxetan) for relapsed or refractory mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma, Mantle-Cell | Phase 2 | Status: COMPLETED